Market Overview

UPDATE: Bank of America Downgrades Abaxis on Growth Concerns, Valuation

Related ABAX
Canaccord Believes Zoetis Could Bid For Idexx Laboratories
Medtronic Has Big Plans For This Device (And It Could Help 500,000 People Each Year)

In a report published Friday, Bank of America analyst Erin E. Wilson downgraded the rating on Abaxis (NASDAQ: ABAX) from Neutral to Underperform, and lowered the price target from $36.00 to $35.00.

In the report, Bank of America noted, “ABAX's shares have increased 11% off of a low in December (vs. +4% S&P 500), despite a string of disappointing earnings reports, recent management turnover, and less traction from its expanded MWI Veterinary Supply distribution relationship. With the stock at a higher value, despite limited clarity on its future growth, we are lowering our rating to Underperform (from Neutral). We are also cutting our 2015E EPS to $0.90 (from $0.95) to reflect a lower contribution from MWI and an evolving competitive landscape that appears increasingly unfavorable for ABAX. Our PO moves to $35 (from $36).”

Abaxis closed on Thursday at $39.15.

Latest Ratings for ABAX

Jul 2015Canaccord GenuityDowngradesBuyHold
Jul 2015Canaccord GenuityMaintainsBuy
Mar 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for ABAX
View the Latest Analyst Ratings

Posted-In: Bank of America Erin E. WilsonAnalyst Color Downgrades Analyst Ratings


Related Articles (ABAX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters